Cell migration is required for a number of physiological processes and is implicated in pathologies such as tumor metastasis. Cell motility is dependent upon dynamic actin reorganization, and is regulated by the Rho family of small GTPases. Rho GTPases are molecular switches that cycle between their active and inactive conformations. The best-studied members of this family are Rac1, RhoA, and Cdc42. Each is responsible for the formation of specific actin structures. Diacylglycerol kinases (DGKs) act at the membrane to convert diacylglycerol (DAG) and phosphatidic acid (PA), maintaining the balance of these two lipid second messengers. Previous studies from our lab have demonstrated that the ζ isoform of DGK facilitates the release of Rac1 and RhoA from their inhibitor, RhoGDI. Here we studied a closely related isoform, DGKι, using mouse embryonic fibroblasts (MEFS) in which the gene for DGKι had been deleted. Aberrations in cell morphology, spreading, and migration were identified in DGKι-null MEFs. We showed that the activity of Rac1 and RhoC, but not RhoA, was impaired in the absence of DGKι, yet only RhoC protein levels were affected. Reduced activation of these Rho GTPases was accompanied by defects in Rac1- and RhoC- related actin structures. These data demonstrate that DGKι, in addition to DGKζ, contributes to the regulation of GTPase activation and remodeling of the actin cytoskeleton.

No description available.

L'agressivité des cancers est souvent liée au pouvoir métastatique des cellules tumorales et la dissémination de ces dernières peut survenir suite à un phénomène appelé la transition épithéliomésenchymateuse. Une analyse de l'expression de la Cycline A2 conduite sur des échantillons humains de tumeurs primaires colorectales et de leurs métastases correspondantes révèle que cette protéine est moins abondante dans ces dernières. Le travail décrit dans cette thèse a permis de relier la Cycline A2 au remodelage du cytosquelette d'Actine dans les fibroblastes. Cette régulation requiert la localisation cytoplasmique de la molécule ainsi que son domaine N-terminal qui ne lie pas les CDKs. Nos expériences suggèrent que cette nouvelle activité est la conséquence d'une liaison directe entre la GTPase RhoA et la Cycline A2. La présence de cette dernière augmente l'activation de RhoA par sa GEF in vitro. L'utilisation de cellules épithéliales mammaires normales a permis l'identification d'un autre partenaire, RhoC. Dans ce contexte cellulaire, l'invalidation de la Cycline A2 diminue l'activation de RhoA et, renforce celle de RhoC ce qui conduit à une augmentation de l'invasion cellulaire en matrice de collagène. Ces cellules acquièrent aussi des propriétés mésenchymateuses caractéristiques de l'EMT, et ce phénotype est exacerbé par la présence de RasV12. Ce travail établit donc l'existence de nouvelles fonctions pour la Cycline A2 qui viennent compléter le tableau de régulation de la motilité par les protéines du cycle cellulaire et contribuent à une meilleure compréhension de son rôle dans le cancer. / Cancer aggressiveness is often associated with metastases occurrence and their dissemination can arise following an epithelial to mesenchymal transition (EMT). Cyclin A2 expression is lower in metastases relative to primary colon adenocarcinoma of matched human tumors. This manuscript describes new links between Cyclin A2 and Actin cytoskeleton remodeling in fibroblasts. This regulation requires a cytoplasmic localization of the protein and its N-terminal domain, which is unable to bind CDKs. This new Cyclin A2 activity appears to be mediated by its binding to RhoA. Accordingly, the activity of its GEF is potentiated when Cyclin A2 is present, in vitro. Furthermore, we used a normal mammary epithelial cell line and identified another Cyclin A2 partner, RhoC. Cyclin A2 depletion in this context leads to a reciprocal RhoGTPase activation where RhoA activation is impaired and that of RhoC is increased. Moreover, cell invasiveness is increased in a collagen matrix following Cyclin A2 knockdown in these cells. In addition, the epithelial cells acquire mesenchymal properties, which are exarcerbated by the expression of RasV12 and are characteristic of an EMT. Our work completes the network involving cell cycle proteins in motility. These novel functions of Cyclin A2 will hopefully help to understand the impact of its deregulation in cancer.